Article
Journal of Medicinal Chemistry, 2010, Vol. 53, No. 11 4377
(20) Kallio, M. J.; McCleland, M. L.; Stukenberg, P. T.; Gorbsky, G. J.
Inhibition of aurora B kinase blocks chromosome segregation,
overrides the spindle checkpoint, and perturbs microtubule
dynamics in mitosis. Curr. Biol. 2002, 12, 900–905.
(21) Warner, S. L.; Munoz, R. M.; Stafford, P.; Koller, E.; Hurley,
L. H.; Von Hoff, D. D.; Han, H. Comparing aurora A and aurora B
as molecular targets for growth inhibition of pancreatic cancer
cells. Mol. Cancer Ther. 2006, 5, 2450–2458.
(22) Manfredi, M. G.; Ecsedy, J. A.; Meetze, K. A.; Balani, S. K.;
Burenkova, O.; Chen, W.; Galvin, K. M.; Hoar, K. M.; Huck, J. J.;
LeRoy, P. J.; Ray, E. T.; Sells, T. B.; Stringer, B.; Stroud, S. G.;
Vos, T. J.; Weatherhead, G. S.; Wysong, D. R.; Zhang, M.; Bolen,
J. B.; Claiborne, C. F. Antitumor activity of MLN8054, an orally
active small-molecule inhibitor of aurora A kinase. Proc. Natl.
Acad. Sci. U.S.A. 2007, 104, 4106–4111.
(23) Yang, H.; Burke, T.; Dempsey, J.; Diaz, B.; Collins, E.; Toth, J.;
Beckmann, R.; Ye, X. Mitotic requirement for aurora A kinase is
bypassed in the absence of aurora B kinase. FEBS Lett. 2005, 579,
3385–3391.
SAR analysis, X-ray crystallography, and biological activity.
J. Med. Chem. 2004, 47, 1662–1675.
(37) Wang, S.; Wood, G.; Meades, C.; Griffiths, G.; Midgley, C.;
McNae, I.; McInnes, C.; Anderson, S.; Jackson, W.; Mezna, M.;
Yuill, R.; Walkinshaw, M.; Fischer, P. M. Synthesis and biological
activity of 2-anilino-4-(1H-pyrrol-3-yl)pyrimidine CDK inhibi-
tors. Bioorg. Med. Chem. Lett. 2004, 14, 4237–4240.
(38) Wu, S. Y.; McNae, I.; Kontopidis, G.; McClue, S. J.; McInnes, C.;
Stewart, K. J.; Wang, S.; Zheleva, D. I.; Marriage, H.; Lane, D. P.;
Taylor, P.; Fischer, P. M.; Walkinshaw, M. D. Discovery of a novel
family of CDK inhibitors with the program LIDAEUS: structural
basis for ligand-induced disordering of the activation loop. Struc-
ture 2003, 11, 399–410.
(39) Griffiths, G.; Midgley, C.; Grabarek, J.; Cooper, M.; Glover, D.;
Ingram, L.; Jackson, W.; Meades, C.; Mezna, M.; O’Boyle, J.;
Wood, G.; Yuill, R.; Lane, D. P.; Jackson, R.; Fischer, P. M.;
Wang, S. Identification and characterization of kinase inhibitors
that inhibit CDK2, CDK7 and CDK 9 activities, induce p53 and
result in reduced proliferationand induction of apoptosis of human
tumor cells. Proc. Am. Assoc. Cancer Res. 2004, 45, Abstract 837.
(40) Wang, S.; Wood, G.; Meades, C.; Griffiths, G.; Midgley, C.;
Grabarek, J.; Cooper, M.; Anderson, S.; Jackson, W.; Yuill, R.;
McNae, I.; McInnes, C.; Zheleva, D.; Walkinshaw, M.; Lane,
D. P.; Jackson, R.; Fischer, P. M. Discovery of 2-phenylamino-
4-(pyrrol-3-yl)-pyrimidines new class of CDK inhibitors: synthesis,
crystal structures, in vitro anti-proliferative activity and biochem-
ical evaluation. Clin. Cancer Res. 2003, 9 (16, Suppl.), Abstract C61.
(41) Bredereck, H.; Effenberger, F.; Botsch, H. Acid amide reactions.
XLV. Reactivity of formamidines, dimethylformamide diethyl
acetal (amide acetal), and bis(dimethylamino)methoxymethane
(aminal ester). Chem. Ber. 1964, 97, 3397–3406.
(42) Orus, L.; Martinez, J.; Perez, S.; Oficialdegui, A. M.; del Castillo,
J. C.; Mourelle, M.; Lasheras, B.; del Rio, J.; Monge, A. New
3-[4-(3-substituted phenyl)piperazin-1-yl]-l-(benzo[b]thiophen-3-
yl)-propanol derivatives with dual action at 5-HT1A serotonin
receptors and serotonin transporter as a new class of antidepres-
sants. Pharmazie 2002, 57, 515–518.
(43) Zhai, S.; Senderowicz, A.; Sausville, E. A.; Figg, W. D. Flavopiri-
dol, a novel cyclin-dependent kinase inhibitor, in clinical develop-
ment. Ann. Pharmacother. 2002, 36, 905–911.
(44) Wang, S.; McClue, S. J.; Ferguson, J. R.; Hull, J. D.; Stokes, S.;
Parsons, S.; Westwood, R.; Fischer, P. M. Synthesis and config-
uration of the cyclin-dependent kinase inhibitor roscovitine and its
enantiomer. Tetrahedron: Asymmetry 2001, 12, 2891–2894.
(45) Fischer, P. M. The use of CDK inhibitors in oncology: a pharma-
ceutical perspective. Cell Cycle 2004, 3, 742–746.
(46) Lu, W.; Chen, L.; Peng, Y.; Chen, J. Activation of p53 by
roscovitine-mediated suppression of MDM2 expression. Oncogene
2001, 20, 3206–3216.
(47) Ljungman, M.; Paulsen, M. T. The cyclin-dependent kinase in-
hibitor roscovitine inhibits RNA synthesis and triggers nuclear
accumulation of p53 that is unmodified at Ser15 and Lys382. Mol.
Pharmacol. 2001, 60, 785–789.
(48) Juan, G.; Traganos, F.; James, W. M.; Ray, J. M.; Roberge, M.;
Sauve, D. M.; Anderson, H.; Darzynkiewicz, Z. Histone H3
phosphorylation and expression of cyclins A and B1 measured in
individual cells during their progression through G2 and mitosis.
Cytometry 1998, 32, 71–77.
(49) Gasparri, F.; Mariani, M.; Sola, F.; Galvani, A. Quantification of
the proliferation index of human dermal fibroblast cultures with
the ArrayScan high-content screening reader. J. Biomol. Screening
2004, 9, 232–243.
(50) Gillespie, D. A.; Walker, M. Mitotic index determination by flow
cytometry. Subcell. Biochem. 2006, 40, 355–358.
(51) Davis, F. M.; Tsao, T. Y.; Fowler, S. K.; Rao, P. N. Monoclonal
antibodies to mitotic cells. Proc. Natl. Acad. Sci. U.S.A. 1983, 80,
2926–2930.
(52) Crosio, C.; Fimia, G. M.; Loury, R.; Kimura, M.; Okano, Y.;
Zhou, H.; Sen, S.; Allis, C. D.; Sassone-Corsi, P. Mitotic phos-
phorylation of histone H3: spatio-temporal regulation by mamma-
lian aurora kinases. Mol. Cell. Biol. 2002, 22, 874–885.
(24) Pollard, J. R.; Mortimore, M. Discovery and development of
aurora kinase inhibitors as anticancer agents. J. Med. Chem.
2009, 52, 2629–2651.
(25) Hauf, S.; Cole, R. W.; LaTerra, S.; Zimmer, C.; Schnapp, G.;
Walter, R.; Heckel, A.; Meel, J. v.; Rieder, C. L.; Peters, J.-M. The
small molecule hesperadin reveals a role for aurora B in correcting
kinetochore-microtubule attachment and in maintaining the spin-
dle assembly checkpoint. J. Cell Biol. 2003, 161, 281–294.
(26) Ditchfield, C.; Johnson, V. L.; Tighe, A.; Ellston, R.; Haworth, C.;
Johnson, T.; Mortlock, A.; Keen, N.; Taylor, S. S. Aurora B
couples chromosome alignment with anaphase by targeting
BubR1, Mad2, and Cenp-E to kinetochores. J. Cell Biol. 2003,
161, 267–280.
(27) Wang, Y.; Serradell, N. VX-680/MK-0457 aurora kinase inhibitor
oncolytic. Drugs Future 2007, 32, 144–147.
(28) Gontarewicz, A.; Brummendorf, T. H. Danusertib (formerly PHA-
739358);a novel combined pan-aurora kinases and third genera-
tion Bcr-Abl tyrosine kinase inhibitor. Recent Results Cancer. Res.
2010, 184, 199–214.
(29) Carpinelli, P.; Ceruti, R.; Giorgini, M. L.; Cappella, P.; Gianellini,
L.; Croci, V.; Degrassi, A.; Texido, G.; Rocchetti, M.; Vianello, P.;
Rusconi, L.; Storici, P.; Zugnoni, P.; Arrigoni, C.; Soncini, C.; Alli,
C.; Patton, V.; Marsiglio, A.; Ballinari, D.; Pesenti, E.; Fancelli, D.;
Moll, J. PHA-739358, a potent inhibitor of aurora kinases with a
selective target inhibition profile relevant to cancer. Mol. Cancer
Ther. 2007, 6, 3158–3168.
(30) Harrington, E. A.; Bebbington, D.; Moore, J.; Rasmussen, R. K.;
Ajose-Adeogun, A. O.; Nakayama, T.; Graham, J. A.; Demur, C.;
Hercend, T.; Diu-Hercend, A.; Su, M.; Golec, J. M. C.; Miller,
K. M. VX-680, a potent and selective small-molecule inhibitor of
the aurora kinases, suppresses tumor growth in vivo. Nat. Med.
2004, 10, 262–267.
(31) Warner, S. L.; Bashyam, S.; Vankayalapati, H.; Bearss, D. J.; Han,
H.; Von Hoff, D. D.; Hurley, L. H. Identification of a lead
small-molecule inhibitor of the aurora kinases using a structure-
assisted, fragment-based approach. Mol. Cancer Ther. 2006, 5,
1764–1773.
(32) Wilkinson, R. W.; Odedra, R.; Heaton, S. P.; Wedge, S. R.; Keen,
N. J.; Crafter, C.; Foster, J. R.; Brady, M. C.; Bigley, A.; Brown, E.;
Byth, K. F.; Barrass, N. C.; Mundt, K. E.; Foote, K. M.; Heron,
N. M.; Jung, F. H.; Mortlock, A. A.; Boyle, F. T.; Green, S.
AZD1152, a selective inhibitor of aurora B kinase, inhibits human
tumor xenograft growth by inducing apoptosis. Clin. Cancer Res.
2007, 13, 3682–3688.
(33) Hoar, K.; Chakravarty, A.; Rabino, C.; Wysong, D.; Bowman, D.;
Roy, N.; Ecsedy, J. A. MLN8054, a small-molecule inhibitor of
aurora A, causes spindle pole and chromosome congression defects
leading to aneuploidy. Mol. Cell. Biol. 2007, 27, 4513–4525.
(34) Kontopidis, G.; McInnes, C.; Pandalaneni, S. R.; McNae, I.;
Gibson, D.; Mezna, M.; Thomas, M.; Wood, G.; Wang, S.;
Walkinshaw, M. D.; Fischer, P. M. Differential binding of inhibi-
tors to active and inactive CDK2 provides insights for drug design.
Chem. Biol. 2006, 13, 201–211.
(35) McInnes, C.; Wang, S.; Anderson, S.; O’Boyle, J.; Jackson, W.;
Kontopidis, G.; Meades, C.; Mezna, M.; Thomas, M.; Wood, G.;
Lane, D. P.; Fischer, P. M. Structural determinants of CDK4
inhibition and design of selective ATP competitive inhibitors.
Chem. Biol. 2004, 11, 525–534.
(36) Wang, S.; Meades, C.; Wood, G.; Osnowski, A.; Anderson, S.;
Yuill, R.; Thomas, M.; Mezna, M.; Jackson, W.; Midgley, C.;
Griffiths, G.; Fleming, I.; Green, S.; McNae, I.; Wu, S.-Y.;
McInnes, C.; Zheleva, D.; Walkinshaw, M. D.; Fischer, P. M.
2-Anilino-4-(thiazol-5-yl)pyrimidine CDK inhibitors: synthesis,
(53) Pascreau, G.; Arlot-Bonnemains, Y.; Prigent, C. Phosphorylation
of histone and histone-like proteins by aurora kinases during
mitosis. Prog. Cell Cycle Res. 2003, 5, 369–374.
(54) Ikezoe, T. Aurora kinases as an anti-cancer target. Cancer Lett.
2008, 262, 1–9.
(55) Giet, R.; McLean, D.; Descamps, S.; Lee, M. J.; Raff, J. W.;
Prigent, C.; Glover, D. M. Drosophila aurora A kinase is required
to localize D-TACC to centrosomes and to regulate astral micro-
tubules. J. Cell Biol. 2002, 156, 437–451.
(56) Giet, R.; Glover, D. M. Drosophila aurora B kinase is required for
histone H3 phosphorylation and condensin recruitment during